Eckert & Ziegler stock holds steady around 13 euros on Xetra

Eckert & Ziegler stock is trading close to 13 euros on Xetra as of September 1, 2026, while investors look at the latest revenue and profit trends from the most recent financial year.

Eckert & Ziegler stock (ISIN DE0005659700) is quoted at 13.06 euros on Xetra as of September 1, 2026, with a modest gain of 0.38% compared to the previous close according to a price overview from finanzen.net. This places the German radiopharmaceutical specialist in a relatively stable price range around the 13 euro mark at the start of September 2026, a level that investors use as a reference for assessing valuation and recent performance.

Share price around 13 euros as of September 1, 2026

According to a detailed quotation page on finanzen.net, Eckert & Ziegler shares most recently traded at 13.06 euros on Xetra on September 1, 2026. The same overview shows an opening price of 13.22 euros and a previous Xetra close of 13.01 euros, implying an intraday gain of 0.38% based on the Xetra comparison. For investors, this means the stock is trading only 0.05 euros above the previous Xetra close, underlining a narrow daily trading range.

The finanzen.net data also list an indicative current price level of 13.01 euros for Eckert & Ziegler shares as of early September 2026 across the consolidated quote overview. In addition, an intraday quotation on the gettex trading venue of 13.22 euros on September 1, 2026 highlights that some trading venues priced the stock slightly higher intraday than the Xetra close. This comparison between the 13.06 euro Xetra level and the 13.22 euro gettex quote shows a spread of 0.16 euros, which can be relevant for investors looking at liquidity and intra-day price differences.

Fundamentals and recent financial performance

The latest complete annual and interim figures for Eckert & Ziegler are not explicitly listed in the same day-filtered sources, but investors typically focus on revenue, earnings and margins from the most recently published financial year and the latest interim report up to September 2026. In the absence of fresh fundamental figures within the last 24 hours in the available price-focused data, the main quantitative anchor for the current assessment remains the market price and its short-term movement around 13 euros. That said, historical figures from previous financial years serve as context rather than as an up-to-date snapshot and therefore are interpreted with caution by market participants.

For a quantified comparison, investors often contrast the current price around 13.06 euros with historical price levels, for example the stock’s previous-year trading range, and with fundamental valuation metrics such as the price-to-earnings ratio derived from the latest available annual earnings. If, for instance, the most recent full-year net profit implies an earnings per share level that leads to a price-to-earnings ratio in the mid-teens at the current price, then the stock might be viewed as reasonably valued compared to other healthcare and radiopharmaceutical companies. In this way, the 13.06 euro price point as of September 1, 2026 is not only a pure quotation but also a reference for relative valuation versus historical profit and peer multiples.

Radiopharmaceutical portfolio as growth driver

Eckert & Ziegler focuses on the production of radioisotopes and radiopharmaceutical components used in nuclear medicine, oncology and related diagnostic applications. The company’s portfolio includes sealed radioactive sources, brachytherapy products and generator systems that supply radionuclides for diagnostic imaging and therapy. For investors, this specialization offers exposure to structural growth trends in cancer diagnosis and treatment, where demand for precise imaging and targeted radiotherapy continues to increase.

A representative product category for Eckert & Ziegler is its brachytherapy solutions, which are used in the local treatment of tumors by placing radioactive sources in or near the tumor tissue. As hospitals and clinics expand their capacities for minimally invasive cancer therapies, demand for reliable and standardized radioactive sources can support the company’s revenue base over time. In addition, Eckert & Ziegler’s activities in supplying radionuclides and components to pharmaceutical partners in radioligand therapy add another growth leg, particularly as more radiopharmaceutical candidates progress through clinical development pipelines in the coming years.

Stock remains a Xetra-traded healthcare name

From an investor perspective, the key takeaway as of September 1, 2026 is that Eckert & Ziegler stock remains a mid-cap healthcare and radiopharmaceutical name listed in Germany and traded on Xetra, with a current Xetra price of 13.06 euros and a narrow day-to-day fluctuation around this level according to the finanzen.net overview. With a consolidated quotation of 13.01 euros and a small positive percentage change on Xetra, the share price currently reflects a balance between growth expectations in radiopharmaceutical markets and the usual volatility associated with mid-cap healthcare stocks. For investors, future catalysts will likely stem from new contract announcements, regulatory approvals and the next set of quarterly or annual results, which will update revenue and earnings figures and thus the valuation metrics tied to the present 13 euro price region.

Eckert & Ziegler at a glance

• Company: Eckert & Ziegler SE
• ISIN: DE0005659700
• WKN: 565970
• Ticker: EUZ
• Trading venue: Xetra
• Price (as of September 1, 2026): 13.06 EUR
• Sector / Industry: Healthcare / Radiopharmaceuticals
• Index membership: TecDAX